Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Guidance history
Kiniksa Pharmaceuticals International (KNSA) guidance history: what it guided and what it reported
Kiniksa Pharmaceuticals International gave guidance in 3 earnings releases on file since Feb 25, 2025. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +18.9% against the guided midpoint. Its releases raised guidance once and lowered it 0 times.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $900M–$920M (Feb 24, 2026) | — | to be reported | — |
| FY2025 | $560M–$580M (Feb 25, 2025) | $678M | above the range | +18.9% |
The latest quarter
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
Does Kiniksa Pharmaceuticals International beat its guidance?
Kiniksa Pharmaceuticals International gave guidance in 3 earnings releases on file since Feb 25, 2025. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +18.9% against the guided midpoint.
How often does Kiniksa Pharmaceuticals International raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since Feb 25, 2025.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.